癌遺伝子治療の世界市場2021年-2025年

◆英語タイトル:Global Cancer Gene Therapy Market 2021-2025
◆商品コード:IRTNTR46595
◆発行会社(リサーチ会社):Technavio
◆発行日:2021年1月8日
◆ページ数:約120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米、ヨーロッパ、アジア太平洋、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

テクナビオ社の本調査レポートでは、世界の癌遺伝子治療市場について調査し、エグゼクティブサマリー、市場状況、市場規模、ファイブフォース分析、治療別(腫瘍溶解性ウイルス治療、遺伝子移植、遺伝子誘導免疫治療)分析、顧客状況、地域別状況、企業状況、企業分析などを掲載しております。
・エグゼクティブサマリー
・市場状況
・市場規模
・ファイブフォース分析
・世界の癌遺伝子治療市場規模:治療別(腫瘍溶解性ウイルス治療、遺伝子移植、遺伝子誘導免疫治療)
・顧客状況
・地域別状況
・企業状況
・企業分析
【レポートの概要】

Global Cancer Gene Therapy Market 2021-2025
Technavio has been monitoring the cancer gene therapy market and it is poised to grow by $ 2.96 bn during 2021-2025 progressing at a CAGR of 20% during the forecast period. Our report on cancer gene therapy market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the side effects of traditional cancer treatments, benefits associated with gene therapy for cancer treatment and the rising prevalence rate of cancer boosting the demand for cancer therapeutics. In addition, the side effects of traditional cancer treatments is anticipated to boost the growth of the market as well.
The cancer gene therapy market analysis includes application segments and geographical landscapes.

Technavio’s cancer gene therapy market is segmented as below:
By Application
• Oncolytic virotherapy
• Gene transfer
• Gene-induced immunotherapy

By Geographical Landscapes
• North America
• Europe
• Asia
• ROW

This study identifies the rising partnerships and collaborations as one of the prime reasons driving the cancer gene therapy market growth during the next few years. Also, favorable government regulations for gene therapy programs and rapid growth potential in developing economies will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on cancer gene therapy market covers the following areas:
• Cancer gene therapy market sizing
• Cancer gene therapy market forecast
• Cancer gene therapy market industry analysis

Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cancer gene therapy market vendors that include Adaptimmune Therapeutics plc, Advantagene Inc., Amgen Inc., Anchiano Therapeutics Ltd., bluebird bio Inc., GlaxoSmithKline Plc, Merck KGaA, Shanghai Sunway Biotech Co. Ltd., Sibiono GeneTech Co. Ltd. Shenzhen (Sibiono), and ZIOPHARM Oncology Inc. . Also, the cancer gene therapy market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit – https://www.technavio.com/report/cancer-gene-therapy-market-industry-analysis
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

【レポートの目次】

• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020 – 2025
• Five Forces Analysis
o Five Forces Summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Therapy
o Market segments
o Comparison by Therapy
o Oncolytic virotherapy – Market size and forecast 2020-2025
o Gene transfer – Market size and forecast 2020-2025
o Gene-induced immunotherapy – Market size and forecast 2020-2025
o Market opportunity by Therapy
• Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2020-2025
o Europe – Market size and forecast 2020-2025
o Asia – Market size and forecast 2020-2025
o ROW – Market size and forecast 2020-2025
o Key leading countries
o Market opportunity by geography
o Volume drivers – Demand led growth
o Market challenges
o Market trends
• Vendor Landscape
o Overview
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Adaptimmune Therapeutics plc
o Advantagene Inc.
o Amgen Inc.
o Anchiano Therapeutics Ltd.
o bluebird bio Inc.
o GlaxoSmithKline Plc
o Merck KGaA
o Shanghai Sunway Biotech Co. Ltd.
o Sibiono GeneTech Co. Ltd. Shenzhen (Sibiono)
o ZIOPHARM Oncology Inc.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations
Exhibit
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global – Market size and forecast 2020 – 2025 ($ million)
• 13: Global market: Year-over-year growth 2020 – 2025 (%)
• 14: Five forces analysis 2020 & 2025
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition – Five forces 2020
• 21: Other1 – Market share 2020-2025 (%)
• 22: Comparison by Other1
• 23: Oncolytic virotherapy – Market size and forecast 2020-2025 ($ million)
• 24: Oncolytic virotherapy – Year-over-year growth 2020-2025 (%)
• 25: Gene transfer – Market size and forecast 2020-2025 ($ million)
• 26: Gene transfer – Year-over-year growth 2020-2025 (%)
• 27: Gene-induced immunotherapy – Market size and forecast 2020-2025 ($ million)
• 28: Gene-induced immunotherapy – Year-over-year growth 2020-2025 (%)
• 29: Market opportunity by Other1
• 30: Customer landscape
• 31: Market share by geography 2020-2025 (%)
• 32: Geographic comparison
• 33: North America – Market size and forecast 2020-2025 ($ million)
• 34: North America – Year-over-year growth 2020-2025 (%)
• 35: Europe – Market size and forecast 2020-2025 ($ million)
• 36: Europe – Year-over-year growth 2020-2025 (%)
• 37: Asia – Market size and forecast 2020-2025 ($ million)
• 38: Asia – Year-over-year growth 2020-2025 (%)
• 39: ROW – Market size and forecast 2020-2025 ($ million)
• 40: ROW – Year-over-year growth 2020-2025 (%)
• 41: Key leading countries
• 42: Market opportunity by geography ($ million)
• 43: Impact of drivers and challenges
• 44: Vendor landscape
• 45: Landscape disruption
• 46: Industry risks
• 47: Vendors covered
• 48: Market positioning of vendors
• 49: Adaptimmune Therapeutics plc – Overview
• 50: Adaptimmune Therapeutics plc – Product and service
• 51: Adaptimmune Therapeutics plc – Key offerings
• 52: Adaptimmune Therapeutics plc – Key customers
• 53: Adaptimmune Therapeutics plc – Segment focus
• 54: Advantagene Inc. – Overview
• 55: Advantagene Inc. – Product and service
• 56: Advantagene Inc. – Key offerings
• 57: Advantagene Inc. – Key customers
• 58: Advantagene Inc. – Segment focus
• 59: Amgen Inc. – Overview
• 60: Amgen Inc. – Business segments
• 61: Amgen Inc. – Key offerings
• 62: Amgen Inc. – Key customers
• 63: Amgen Inc. – Segment focus
• 64: Anchiano Therapeutics Ltd. – Overview
• 65: Anchiano Therapeutics Ltd. – Business segments
• 66: Anchiano Therapeutics Ltd. – Key offerings
• 67: Anchiano Therapeutics Ltd. – Key customers
• 68: Anchiano Therapeutics Ltd. – Segment focus
• 69: bluebird bio Inc. – Overview
• 70: bluebird bio Inc. – Business segments
• 71: bluebird bio Inc. – Key offerings
• 72: bluebird bio Inc. – Key customers
• 73: bluebird bio Inc. – Segment focus
• 74: GlaxoSmithKline Plc – Overview
• 75: GlaxoSmithKline Plc – Business segments
• 76: GlaxoSmithKline Plc – Key offerings
• 77: GlaxoSmithKline Plc – Key customers
• 78: GlaxoSmithKline Plc – Segment focus
• 79: Merck KGaA – Overview
• 80: Merck KGaA – Business segments
• 81: Merck KGaA – Key offerings
• 82: Merck KGaA – Key customers
• 83: Merck KGaA – Segment focus
• 84: Shanghai Sunway Biotech Co. Ltd. – Overview
• 85: Shanghai Sunway Biotech Co. Ltd. – Product and service
• 86: Shanghai Sunway Biotech Co. Ltd. – Key offerings
• 87: Shanghai Sunway Biotech Co. Ltd. – Key customers
• 88: Shanghai Sunway Biotech Co. Ltd. – Segment focus
• 89: Sibiono GeneTech Co. Ltd. Shenzhen (Sibiono) – Overview
• 90: Sibiono GeneTech Co. Ltd. Shenzhen (Sibiono) – Product and service
• 91: Sibiono GeneTech Co. Ltd. Shenzhen (Sibiono) – Key offerings
• 92: Sibiono GeneTech Co. Ltd. Shenzhen (Sibiono) – Key customers
• 93: Sibiono GeneTech Co. Ltd. Shenzhen (Sibiono) – Segment focus
• 94: ZIOPHARM Oncology Inc. – Overview
• 95: ZIOPHARM Oncology Inc. – Product and service
• 96: ZIOPHARM Oncology Inc. – Key offerings
• 97: ZIOPHARM Oncology Inc. – Key customers
• 98: ZIOPHARM Oncology Inc. – Segment focus
• 99: Currency conversion rates for US$
• 100: Research Methodology
• 101: Validation techniques employed for market sizing
• 102: Information sources
• 103: List of abbreviations



【掲載企業】

Adaptimmune Therapeutics plc, Advantagene Inc., Amgen Inc., Anchiano Therapeutics Ltd., bluebird bio Inc., GlaxoSmithKline Plc, Merck KGaA, Shanghai Sunway Biotech Co. Ltd., Sibiono GeneTech Co. Ltd. Shenzhen (Sibiono), ZIOPHARM Oncology Inc. 

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[癌遺伝子治療の世界市場2021年-2025年]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆